样式: 排序: IF: - GO 导出 标记为已读
-
The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-14
Abstract Belinostat was approved in 2014 for the treatment of relapsed or refractory peripheral T-cell lymphoma, however, there was insufficient data to recommend a dose in patients with moderate to severe hepatic impairment. The purpose of this analysis was to characterize the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers and varying degrees of
-
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-13 Atsushi Ogawa, Hiroshi Kawamoto, Junichi Hara, Atsushi Kikuta, Chitose Ogawa, Hiroaki Hiraga, Kenichi Yoshimura, Kazunari Miyairi, Reiko Omori, Tokihiro Ro, Yuna Kamei, Toshimi Kimura
-
Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-08
Abstract Purpose An oral docetaxel formulation boosted by the Cytochrome P450 (CYP) 3 A inhibitor ritonavir, ModraDoc006/r, is currently under clinical investigation. Based on clinical data, the incidence of grade 1–2 diarrhea is increased with this oral docetaxel formulation compared to the conventional intravenous administration. Loperamide, a frequently used diarrhea inhibitor, could be added to
-
Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-κB signaling and reducing NLRP3 expression in triple-negative breast cancer Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-08 Wei Zheng, Wei Peng, Fuyong Qian, Mingshuai Zhang, Bofeng Duan, Zhifeng Fan, Yi Xie, Xiaoying Fu
-
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-08
Abstract Purpose Treatment with regorafenib, which inhibits vascular endothelial growth factor (VEGF) receptor, frequently results in hand-foot skin reaction (HFSR), requiring treatment discontinuation or dose reduction. In our prospective study of regorafenib on patients with metastatic colorectal cancer, 17% of patients developed grade 3 HFSR. Herein, we retrospectively examined genetic polymorphisms
-
Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-08 Takashi Masuda, Taro Funakoshi, Takahiro Horimatsu, Shinya Yamamoto, Takeshi Matsubara, Sho Masui, Shunsaku Nakagawa, Yasuaki Ikemi, Motoko Yanagita, Manabu Muto, Tomohiro Terada, Atsushi Yonezawa
-
Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-07
Abstract Capecitabine (CAP) is one of the fluoropyrimidine deoxynucleoside carbamates, which can be converted to 5-fluorouracil (5-FU) by thymine deoxynucleoside phosphorylase (dThdPase) to exert antitumor effects. The purpose of this study is to compare the pharmacokinetics (PK), bioequivalence (BE), and safety of two CAP tablets in Chinese patients with solid tumor cancer. The results showed that
-
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-07 Colby S. Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan, Qi Liu, Yih-Wen Chen, Benjamin Wu, Qiong Wu, Xian Wang
-
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-05 Jaya Shree Dilli Batcha, Vikram Gota, Saikumar Matcha, Arun Prasath Raju, Mahadev Rao, Karthik S. Udupa, Surulivelrajan Mallayasamy
-
Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-04 Kadriye Bir Yücel, Uguray Aydos, Osman Sütcüoglu, Atiye Cenay Karabörk Kılıç, Nuriye Özdemir, Ahmet Özet, Ozan Yazıcı
-
Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-02 Wenqiang Qu, Jialing Lu, Yujie Ji, Zhewei He, Mengjia Hou, Dongyang Li, Yan Yang, Dan Liu, Suning Chen
-
Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-02
Abstract Immuno-oncology (IO) therapies have changed the cancer treatment landscape. Immune checkpoint inhibitors (ICIs) have improved overall survival in 20–40% of patients with malignancies that were previously refractory. Due to the uniqueness in biology, modalities and patient responses, drug development strategies for IO differed from that traditionally used for cytotoxic and target therapies
-
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-03-01 Cedric Lau, Ma Ida Mohmaed Ali, Lishi Lin, Dorieke E. M. van Balen, Bart A. W. Jacobs, Bastiaan Nuijen, Robert M. Smeenk, Neeltje Steeghs, Alwin D. R. Huitema
-
Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children’s Research Hospital Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-28 Alyssa Gaietto, John C Panetta, Jennifer L Pauley, Mary V Relling, Raul Ribeiro, Matthew J Ehrhardt, Ching-Hon Pui, Hiroto Inaba, Hope D Swanson
-
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-27 Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
-
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-26
Abstract Purpose To evaluate the safety, tolerability, pharmacodynamics (PD), and potential efficacy of zosuquidar (Zos) in combination with daunorubicin and cytarabine in elderly patients with newly diagnosed acute myeloid leukemia (AML). Methods Patients with AML (N = 106) were treated with Zos as a 72-h continuous intravenous (CIV) infusion along with chemotherapy. Leukemic blasts from the patients
-
Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-25 Zhuoyuan Yu, Haifan Xu, Miao Feng, Liqun Chen
-
18β-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-21 Xuan Ma, Zhenou Sun, Hui Chen, Lixing Cao, Shuang Zhao, Lihong Fan, Chong Zhao, Shutao Yin, Hongbo Hu
-
Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001) Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-19
Abstract Purpose The high recurrence rate of colorectal cancer liver metastasis (CRCLM) after surgery remains a crucial problem. However, adjuvant chemotherapy after hepatectomy for CRCLM has not yet been established. This study evaluated the efficacy of adjuvant therapy with S-1 and oxaliplatin (SOX). Methods In a multicenter, randomized, phase II study, patients undergoing curative resection of CRCLM
-
Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-08
Abstract Purpose Doxorubicin is a widely used chemotherapeutic drug that can be administered intravenously as both a bolus infusion and a continuous infusion. The latter is believed to lower the risk of cardiotoxicity, which is a critical long-term complication of doxorubicin treatment. The local tissue concentrations of doxorubicin will be reflected in both treatment efficacy and toxicity, but very
-
Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-07
Abstract Purpose Myelosuppressive chemotherapy-induced neutropenia (CIN) remains a major limitation of cancer treatment efficacy, necessitating very expensive supportive care. Lithium carbonate, an inexpensive drug, can increase the number of neutrophils, possibly providing an efficacious and cost-effective alternative for treating CIN. The aim of this study was to determine whether lithium therapy
-
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-02 Vikram Malhi, Malgorzata Nowicka, Ya-Chi Chen, Priya Agarwal, Marie Waldvogel, Yi Ting Kayla Lien, Marc Hafner, Pablo Perez-Moreno, Heather M. Moore, Jiajie Yu
-
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-02-01 Xiaoya Ma, Yujie Li, Xufeng Zang, Jinping Guo, Wenqian Zhou, Junhui Han, Jing Liang, Panpan Wan, Hua Yang, Tianbo Jin
-
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-01-27 Alexandr N. Chernov, Alexandr V. Kim, Sofia S. Skliar, Evgeniy V. Fedorov, Anna N. Tsapieva, Tatiana A. Filatenkova, Aleksei L. Chutko, Marina V. Matsko, Elvira. S. Galimova, Olga V. Shamova
-
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-01-27
Abstract Purpose Report pharmacokinetic (PK)/pharmacodynamic (PD) findings from the phase III ClarIDHy study and any association between PK/PD parameters and treatment outcomes in this population. Methods Patients with mutant isocitrate dehydrogenase 1 (mIDH1) advanced cholangiocarcinoma were randomized at a 2:1 ratio to receive ivosidenib or matched placebo. Crossover from placebo to ivosidenib was
-
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-01-25
Abstract Purpose Midostaurin, approved for treating FLT-3-mutated acute myeloid leukemia and advanced systemic mastocytosis, is metabolized by cytochrome P450 (CYP) 3A4 to two major metabolites, and may inhibit and/or induce CYP3A, CYP2B6, and CYP2C8. Two studies investigated the impact of midostaurin on CYP substrate drugs and oral contraceptives in healthy participants. Methods Using sentinel dosing
-
Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-01-19 Qian Tan, A. M. Joshua, M. Wang, R. G. Bristow, B. G. Wouters, C. J. Allen, Ian F. Tannock
-
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-01-16 Thamir M. Mahgoub, Emmet J. Jordan, Amira F. Mahdi, Veronika Oettl, Stefanie Huefner, Norma O’Donovan, John Crown, Denis M. Collins
-
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-01-11 Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, Shoyo Shibata, Toshio Shimizu
-
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-01-09 Chong-Zhi Wang, Chunping Wan, Cang-Hai Li, Guo-Gang Liang, Yun Luo, Chun-Feng Zhang, Qi-Hui Zhang, Qinge Ma, Angela H. Wang, Mallory Lager, Ting-Liang Jiang, Lifei Hou, Chun-Su Yuan
-
Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2024-01-04 Feng Yu, Hongjie Huo, Qiong Tang
-
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-12-29 Ramakrishna Nirogi, Jyothsna Ravula, Vijay Benade, Vinod Kumar Goyal, Santosh Kumar Pandey, Dhanunjay Dogiparti, Pradeep Jayarajan, Ilayaraja Kalaikadhiban, Satish Jetta, Veera Raghava Chowdary Palacharla
-
Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-12-26 Yoshiharu Suzuki, Shingo Ishiguro, Hirokazu Shimada, Masahiro Ohgami, Mika Suzuki
-
Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-12-26
Abstract Background Burkitt’s lymphoma, one of the most common subtypes of pediatric malignant lymphoma, is notorious for its swift onset, aggressive proliferation, pronounced invasiveness, and marked malignancy. The therapeutic landscape for Burkitt’s lymphoma currently falls short of providing universally effective and tolerable solutions. Andrographolide, a primary active component of Andrographis
-
Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-12-23
Abstract Purpose Cervical cancer (CC) ranks as the fourth most prevalent malignancy among women worldwide, necessitating effective therapeutic interventions to mitigate its detrimental impact on both physical and mental health. Parthenolide (PTL), a natural product of the sesquiterpene lactone derived from Feverfew leaves, has exhibited promising anti-tumor properties in previous studies; however,
-
Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-12-20 Shinji Kobuchi, Atsuko Morita, Shizuka Jonan, Kikuko Amagase, Yukako Ito
-
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-12-17 K. Westerdijk, S. D. Krens, N. Steeghs, W. T. A. van der Graaf, E. T. T. L. Tjwa, H. Westdorp, I. M. E. Desar, N. P. van Erp
-
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-12-13 Nobuaki Matsubara, Shota Kusuhara, Noboru Yamamoto, Kazuki Sudo, Masahiko Yanagita, Kosho Murayama, Hisashi Kawasumi, Deanna L. Russell, Da Yin, Toshio Shimizu
-
Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/β-catenin signaling pathway in breast cancer Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-12-05 Shengxi Xu, Yingfang Shi, Sen Li
-
Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-12-01 Xingyi Lin, Ying Tan, Lele Pan, Zhenfeng Tian, Lijun Lin, Mingxin Su, Guangsheng Ou, Yinting Chen
-
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-30 Carla Biesdorf, Xiaowen Guan, Satya R. Siddani, David Hoffman, Nils Boehm, Bruno C. Medeiros, Toshihiko Doi, Maja de Jonge, Drew Rasco, Rajeev M. Menon, Akshanth R. Polepally
-
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-27 Arjun Mittra, Geraldine H. O’ Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Lawrence Rubinstein, Lamin Juwara, Deborah Wilsker, Jiuping Ji, Brandon Miller, Tony Navas, Katherine V. Ferry-Galow, Andrea Regier Voth, Ting-Chia Chang, Shahanawaz Jiwani, Ralph E. Parchment, James H. Doroshow, Alice P. Chen
-
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-28 Hiroaki Takahashi, Yoko Saito, Kanon Sugawara, Masaki Sato, Tomohiko Tairabune, Haruki Ujiie, Junichi Asaka, Kenzo Kudo
-
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-13 Yizhe Chen, David Wyatt, Massimo Attanasio, Mark Thomas, Michael Thomas, Bing He, Rina Nishii, Liangang Liu, Vivian Shan, Yongjun Xue, Leonidas N. Carayannopoulos, Ken Ogasawara, Gopal Krishna
-
Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy? Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-13 Mourad Hamimed, Raynier Devillier, Pierre-Jean Weiller, Clémence Marin, Jean-Marc Schiano, Nawel Belmecheri, Marie-Christine Etienne-Grimaldi, Joseph Ciccolini, Samia Harbi
-
Azithromycin in cancer treatment: envisioning the probable link of mitochondrial dysfunction and necroptosis. Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-14 Siti Nazihahasma Hassan,Farizan Ahmad
-
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-07 Martina Catalano, Andrea Lapucci, Stefania Nobili, Irene De Gennaro Aquino, Ismaela Anna Vascotto, Lorenzo Antonuzzo, Donata Villari, Gabriella Nesi, Enrico Mini, Giandomenico Roviello
-
CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-08 Yuanpei Wang, Jing Wen, Xiangyi Sun, Yi Sun, Yuchen Liu, Xiaoran Cheng, Weijia Wu, Qianwen Liu, Fang Ren
-
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC? Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-07 Angeline Ginzac, Emilie Thivat, Caroline Petorin, Damien Richard, Pauline Herviou, Ioana Molnar, Hervé Devaud, Isabelle Creveaux, Florent Ferrer, Nicolas Authier, Marine Jary, Denis Pezet, Xavier Durando
-
Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-05 Xinyu Wang, Shujun Gu, Jingli Wen, Lixi Zhang, Xu Qi
-
Effect of vitamin E on doxorubicin and paclitaxel-induced memory impairments in male rats Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-06 Ahmad A. Altarifi, Kareem Sawali, Karem H. Alzoubi, Tareq Saleh, Malik Abu Al-Rub, Omar Khabour
-
The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-03 Yukio Tonozuka, Hiroshi Tanaka, Kazumi Nomura, Kazuya Sakaguchi, Junpei Soeda, Yoshihide Kakimoto
-
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-11-03 M. Berge, J. S. Giraud, S. De Percin, A. Puszkiel, A. Thomas-Schoemann, B. Blanchet
-
Are novel oral oncolytics underdosed in obese patients? Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-10-31 Lishi Lin, Ellen K. O. van der Meer, Neeltje Steeghs, Jos H. Beijnen, Alwin D. R. Huitema
-
Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-10-28 Yao Liang, Osamu Maeda, Kazushi Miyata, Mitsuro Kanda, Shizuki Sugita, Dai Shimizu, Kazuki Nishida, Yasuhiro Kodera, Yuichi Ando
Purpose This study aimed to explore associations between genetic polymorphisms and adverse effects due to preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for esophageal cancer. Methods Preoperative DCF (docetaxel, 70 mg/m2/day, day 1; cisplatin, 70 mg/m2/day, day 1; fluorouracil, 750 mg/m2/day, days 1–5) was repeated every 3 weeks for up to three cycles. Genotyping of nine
-
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-10-14 Liangang Chen, Na Yao, Hongjie Yang, Shaofeng Zhang, Kai Zhang
-
Bidirectional pharmacokinetic drug interactions between olaparib and metformin Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-10-10 Joanna Stanisławiak-Rudowicz, Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Filip Otto, Tomasz Grabowski, Anna Wolc, Edmund Grześkowiak, Edyta Szałek
-
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-10-03 Marie Lambert, Mathieu Alonso, Caroline Munzer, Marie-Christine Zimoch, Laurence Malard, Marion Gambart, Marie-Pierre Castex, Carla Martins, Marlène Pasquet, Etienne Chatelut
-
Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-09-28 Mohamed J. Saadh, Muhammad Ali Abdulllah Almoyad, Meryelem Tania Churampi Arellano, Renato R. Maaliw, Roxana Yolanda Castillo-Acobo, Sarah Salah Jalal, Kumaraswamy Gandla, Mohammed Obaid, Asmaa Jamal Abdulwahed, Azher A. Ibrahem, Ioan Sârbu, Ashima Juyal, Natrayan Lakshmaiya, Reza Akhavan-Sigari
-
Sodium orthovanadate exhibits anti-angiogenic, antiapoptotic and blood glucose-lowering effect on colon cancer associated with diabetes Cancer Chemother. Pharmacol. (IF 3.0) Pub Date : 2023-09-27 Kruti Patel, Vivek Bora, Bhoomika Patel